Immune checkpoint inhibitor (ICI) therapy targeting the PD-1/PD-L1/CTLA-4 pathway has been approved for the treatment of more than 10 cancer types (Callahan et al., 2016; Hoos, 2016). The gene discussed is CTLA4; the disease is cancer.